Another preclinical study demonstrated that the combination of CD47 mAb Hu5F9-G4 and trastuzumab in the treatment of Her2+ breast cancer cells significantly overcame the resistance to trastuzumab monotherapy and effectively inhibited tumor growth [157]. The gene discussed is ERBB2; the disease is breast carcinoma.